Key result
GYY4137, an H2S donor, reduced plaque formation and inflammatory markers in diabetes-accelerated atherosclerotic cells and mouse models by inhibiting NLRP3 inflammasome activation.
Why the study?
Does GYY4137 reduce plaque formation and inflammation in diabetes-accelerated atherosclerotic cells and mouse models?
Does GYY4137 reduce plaque formation and inflammation in diabetes-accelerated atherosclerotic cells and mouse models?
The H2S donor GYY4137 protects against diabetes-accelerated atherosclerosis by inhibiting NLRP3 inflammasome activation in preclinical models.
Supports GYY4137 in preclinical diabetic atherosclerosis models; leaves open human translation pending clinical trials.
Hydrogen sulfide (H2S) is an important messenger for its strong anti-inflammatory effects, which may be involved in multiple cardiovascular diseases. In our previous study, we revealed that H2S attenuated diabetes-accelerated atherosclerosis through suppressing oxidative stress. Here we report that GYY4137, a H2S donor, reduced the plaque formation of aortic roots and the levels of both intercellular cell adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) in diabetes-accelerated atherosclerotic cells and mouse models. The inflammatory factors of TNF-α, IL-1β, IL-6, and MCP1 were also significantly reduced by GYY4137. Mechanically, GYY4137 suppressed the activation of pyrin domain containing protein 3 (NLRP3) inflammasome in diabetes-accelerated atherosclerosis conditions. Upon knockdown of NLRP3, the increase of ICAM1 and VCAM1 caused by high glucose and oxLDL could be reversed, indicating that H2S protected the endothelium by inhibiting the activity of NLRP3 inflammasome. In conclusion, our study indicates that GYY4137 effectively protects against the development of diabetes-accelerated atherosclerosis by inhibiting inflammasome activation.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2019) studied Diabetes-accelerated atherosclerosis. GYY4137 (H2S donor) was evaluated on Plaque formation, adhesion molecules (ICAM1, VCAM1), and inflammatory factors. GYY4137, an H2S donor, reduced plaque formation and inflammatory markers in diabetes-accelerated atherosclerotic cells and mouse models by inhibiting NLRP3 inflammasome activation.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: